Gubra – Company Introduction

Meet and ask questions directly to Gubra CEO Henrik Blou and CFO Kristian Borbos when they give an introduction to the company and investment case on 13 June at 10.00 am CEST.
Gubra is a new company in the HCA space and we look forward to learning more about the investment case.

Gubra is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organized in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 200 employees and had annual revenue of approx. DKK 200 million in 2022. Gubra was listed on Nasdaq Copenhagen in the spring of 2023.

Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 09.45 AM, 7 June 2023.